New Cancer Weapon: FDA Approves First-Ever CELMoD Drug for Multiple Myeloma

The FDA just approved Zenbexus (iberdomide), the first drug in a brand-new class called CELMoDs, for treating relapsed or advanced multiple myeloma. This isn't just another pill—it's a protein degrader designed to attack the cancer more powerfully than older drugs like thalidomide. It's approved for use with Darzalex and dexamethasone in patients who've already tried at least one prior therapy.

The key trial, EXCALIBER-RRMM, showed a major win: 41% of patients on...